ADMA Biologics Faces Class Action Over Revenue Allegations

Investors who acquired ADMA Biologics stock between August 9, 2024, and March 25, 2026, are now represented in a newly filed securities class action. The lawsuit claims the biopharmaceutical firm misled shareholders by allegedly inflating revenue figures through channel stuffing and failing to disclose related-party transactions.

The legal action, initiated by the firm Robbins LLP, targets practices that reportedly masked the company's true financial health. According to the complaint, ADMA Biologics maintained inadequate internal controls and misrepresented its operational growth to the market. These claims center on a March 2026 report from Culper Research, which suggested the company utilized a distributor named Genesis BioPharma Services—an entity allegedly operating out of ADMA’s own headquarters—to artificially bolster sales figures.

The market reaction to these allegations was swift. Following the release of the report, ADMA shares plummeted 16.6% on March 24, 2026, and dropped another 15% the following day, closing at $11.33. Investors seeking to participate in the class action or act as a lead plaintiff may contact Robbins LLP, which operates on a contingency fee basis for this litigation. Participation is optional, and shareholders who choose not to take action remain eligible for potential recovery as absent class members.